Laboratory Testing for Ferroportin Disease
Order transferrin saturation (TSAT), serum ferritin, complete blood count with reticulocytes, and consider liver MRI for iron quantification; the hallmark finding is elevated ferritin with low-to-normal TSAT (<45%), distinguishing it from other forms of hemochromatosis.
Initial Laboratory Panel
The diagnostic workup requires specific iron studies 1:
- Transferrin saturation (TSAT): Calculate from serum iron and transferrin or TIBC
- Serum ferritin: Typically markedly elevated
- Complete blood count with reticulocytes: Essential to exclude anemia and red cell disorders
Typical Laboratory Findings in Ferroportin Disease
Classical Ferroportin Disease (65.5% of cases)
The distinguishing biochemical pattern includes 2, 3, 4:
- Elevated serum ferritin: Often markedly elevated (mean ~1,351 μg/L in affected cohorts)
- Normal or low transferrin saturation: Typically <45% (this is the key differentiating feature)
- Inappropriately low TSAT relative to ferritin level: Iron is trapped in macrophages and cannot be released to transferrin
- Tendency toward anemia: May develop with phlebotomy or at menarche due to impaired iron mobilization
Non-Classical SLC40A1-Related Hemochromatosis (34.5% of cases)
A subset presents differently 2, 3:
- Elevated serum ferritin: Similar to classical form
- Elevated transferrin saturation: >45% (resembles HFE hemochromatosis)
- Higher risk of hepatic fibrosis: Associated with the elevated TSAT pattern
- More severe hepatic iron overload: Parenchymal iron deposition predominates
The TSAT level is the critical discriminator between these two phenotypes and guides risk stratification, as elevated TSAT correlates with fibrosis risk 2.
Advanced Diagnostic Testing
Liver Biopsy Findings
When liver biopsy is performed 5:
- Iron distribution pattern: Predominantly in reticuloendothelial cells (Kupffer cells) in classical disease, or mixed hepatocyte/reticuloendothelial pattern without periportal predominance
- Hepatic iron concentration (HIC): Elevated, often higher than in HFE hemochromatosis 2
- Fibrosis: Present in only 11% of cases overall 3, but more common in non-classical phenotype with elevated TSAT
Liver biopsy is recommended for diagnosis and prognosis in patients with phenotypic markers of iron overload who are not C282Y homozygotes or compound heterozygotes 5.
MRI Imaging
Abdominal MRI is the key non-invasive diagnostic tool 4:
- SSL triad: Characteristic iron loading in Spleen, Spine, and Liver
- Splenic iron concentration: Markedly elevated (distinguishes from HFE hemochromatosis)
- Hepatic iron quantification: Shows elevated HIC without requiring biopsy
The splenic iron accumulation on MRI is pathognomonic for ferroportin disease and helps differentiate it from HFE-related hemochromatosis where the spleen is typically iron-spared.
Genetic Testing
- SLC40A1 gene sequencing: Confirms diagnosis by identifying pathogenic variants
- High penetrance: Hyperferritinemia present in 86% of individuals with ferroportin mutations 3
- Autosomal dominant inheritance: 50% risk for siblings and offspring 4
The most recent EASL guidelines 1 recommend that in patients with elevated TSAT and ferritin, non-HFE gene sequencing should encompass a panel including HFE, HJV, TFR2, CP, and SLC40A1.
Additional Laboratory Monitoring
- Liver enzymes (ALT, AST): Evaluate for hepatocellular injury
- Hemoglobin monitoring: Essential before and during phlebotomy due to anemia risk
- Serum hepcidin-25: May be elevated and parallel with ferritin 6, though not routinely available
Critical Pitfalls to Avoid
- Do not assume elevated ferritin always means HFE hemochromatosis: Check TSAT—if normal or low with high ferritin, consider ferroportin disease
- Do not aggressively phlebotomize without monitoring hemoglobin: Classical ferroportin disease patients are prone to anemia due to impaired iron mobilization from macrophages 4
- Do not overlook family screening: This is an autosomal dominant condition with high penetrance requiring genetic counseling 4
- Recognize phenotypic variability: The same mutation can present with different TSAT patterns; genotype-phenotype correlation is limited 2, 7
Risk Stratification Based on Laboratory Results
Patients with SLC40A1-related hemochromatosis (TSAT >45%) have higher risk of chronic liver disease and fibrosis compared to those with classical ferroportin disease 2. This TSAT threshold should guide the intensity of monitoring and consideration for liver biopsy when ferritin exceeds 1,000 μg/L or liver enzymes are elevated 5.